FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

Ahmed Mostafa; Ahmed Kandeil; Yaseen A. M. M. Elshaier; Omnia Kutkat; Yassmin Moatasim; Adel A. Rashad; Mahmoud Shehata; Mokhtar R. Gomaa; Noura Mahrous; Sara H. Mahmoud; Mohamed GabAllah; Hisham Abbas; Ahmed El Taweel; Ahmed E. Kayed; Mina Nabil Kamel; Mohamed El Sayes; Dina B. Mahmoud; Rabeh El-Shesheny; Ghazi Kayali; Mohamed A. Ali

doi:10.3390/ph13120443

Back

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

Journal article

Open access

Peer reviewed

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

Ahmed Mostafa, Ahmed Kandeil, Yaseen A. M. M. Elshaier, Omnia Kutkat, Yassmin Moatasim, Adel A. Rashad, Mahmoud Shehata, Mokhtar R. Gomaa, Noura Mahrous, Sara H. Mahmoud, …

Pharmaceuticals (Basel, Switzerland), v 13(12), 443

04 Dec 2020

DOI: https://doi.org/10.3390/ph13120443

PMID: 33291642

Featured in Collection : UN Sustainable Development Goals @ Drexel

Files and links (1)

url

https://doi.org/10.3390/ph13120443View

Published, Version of Record (VoR)CC BY V4.0, Open

Abstract

Chemistry, Medicinal

Life Sciences & Biomedicine

Pharmacology & Pharmacy

Science & Technology

(1) Background: Drug repositioning is an unconventional drug discovery approach to explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to alleviate the COVID-19 pandemic disease. (2) Methods: Herein, we tested the antiviral activity of anti-microbial and anti-inflammatory Food and Drug Administration (FDA)-approved drugs, commonly prescribed to relieve respiratory symptoms, against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the viral causative agent of the COVID-19 pandemic. (3) Results: Of these FDA-approved antimicrobial drugs, Azithromycin, Niclosamide, and Nitazoxanide showed a promising ability to hinder the replication of a SARS-CoV-2 isolate, with IC50 of 0.32, 0.16, and 1.29 mu M, respectively. We provided evidence that several antihistamine and anti-inflammatory drugs could partially reduce SARS-CoV-2 replication in vitro. Furthermore, this study showed that Azithromycin can selectively impair SARS-CoV-2 replication, but not the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). A virtual screening study illustrated that Azithromycin, Niclosamide, and Nitazoxanide bind to the main protease of SARS-CoV-2 (Protein data bank (PDB) ID: 6lu7) in binding mode similar to the reported co-crystalized ligand. Also, Niclosamide displayed hydrogen bond (HB) interaction with the key peptide moiety GLN: 493A of the spike glycoprotein active site. (4) Conclusions: The results suggest that Piroxicam should be prescribed in combination with Azithromycin for COVID-19 patients.

Metrics

22 Record Views

127 citations in Web of Science

129 citations in Scopus

Details

Title: FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2
Creators: Ahmed Mostafa - National Research Centre
Ahmed Kandeil - National Research Centre
Yaseen A. M. M. Elshaier - University of Sadat City
Omnia Kutkat - National Research Centre
Yassmin Moatasim - National Research Centre
Adel A. Rashad - Drexel University
Mahmoud Shehata - National Research Centre
Mokhtar R. Gomaa - National Research Centre
Noura Mahrous - National Research Centre
Sara H. Mahmoud - National Research Centre
Mohamed GabAllah - National Research Centre
Hisham Abbas - Zagazig University
Ahmed El Taweel - National Research Centre
Ahmed E. Kayed - National Research Centre
Mina Nabil Kamel - National Research Centre
Mohamed El Sayes - National Research Centre
Dina B. Mahmoud - National Organization for Drug Control and Research
Rabeh El-Shesheny - National Research Centre
Ghazi Kayali - The University of Texas Health Science Center at Houston
Mohamed A. Ali - National Research Centre
Publication Details: Pharmaceuticals (Basel, Switzerland), v 13(12), 443
Publisher: Mdpi
Number of pages: 24
Grant note: HHSN272201400006C / National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); NIH National Institute of Neurological Disorders & Stroke (NINDS) MP120801 / NRC; National Research Centre (NRC) 7303 / Egyptian Academy of Scientific Research and Technology (ASRT) within the "Ideation Fund" program
Resource Type: Journal article
Language: English
Academic Unit: Biochemistry and Molecular Biology; Microbiology and Immunology
Web of Science ID: WOS:000602366800001
Scopus ID: 2-s2.0-85097556146
Other Identifier: 991020172708004721

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Web of Science research areas: Chemistry, Medicinal; Pharmacology & Pharmacy

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

Files and links (1)

Abstract

Metrics

Details

UN Sustainable Development Goals (SDGs)

InCites Highlights

Drexel University Social media